N. Curtin

发表

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

R. Mangano, J. Sludden, Y. Drew, 2016, British Journal of Cancer.

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.

N. Curtin, J. K. Porteous, S. Boulton, 1995, British Journal of Cancer.

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

M. Noble, J. Endicott, N. Curtin, 2003, Bioorganic & medicinal chemistry letters.

Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

Jane A. Endicott, Thomas G. Davies, Nicola J. Curtin, 2002, Nature Structural Biology.

Targeting the S and G2 checkpoint to treat cancer.

N. Curtin, P. Stephens, Tao Chen, 2012, Drug discovery today.

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation

N. Curtin, N. Zaffaroni, I. Hardcastle, 2005, Molecular Cancer Therapeutics.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer

S. Duffy, A. Howell, I. Dos Santos Silva, 2013, Breast Cancer Research.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

N. Curtin, B. Durkacz, D. Newell, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Thomas Helleday, N. Curtin, T. Helleday, 2005, Nature.

Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked

N. Curtin, D. Newell, Lan Z. Wang, 2008, Cell cycle.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer

I. Ellis, A. Green, N. Curtin, 2016, Molecular oncology.

Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer

Graham Ball, Devika Agarwal, Ian O Ellis, 2015, Molecular oncology.

A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer

Valerie Speirs, Andrew G. Hall, Nicola J. Curtin, 2008, Breast Cancer Research and Treatment.

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

L. Johnson, M. Noble, J. Endicott, 2003, Bioorganic & medicinal chemistry letters.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Thomas Helleday, Nicola J. Curtin, N. Curtin, 2007, Nature.

Development of pharmacodynamic biomarkers for ATR inhibitors

N. Curtin, P. Reaper, Tao Chen, 2015, Molecular oncology.

The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis

N. Curtin, R. Edmondson, A. McCormick, 2014, PloS one.

Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination

N. Curtin, D. Newell, C. Cano, 2011, Cancer Chemotherapy and Pharmacology.

Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.

N. Curtin, Graeme C. Smith, G. Smith, 2009, International journal of radiation oncology, biology, physics.

PARP Inhibitors and Cancer Therapy

N. Curtin, 2006 .

The Novel Poly(ADP-Ribose) Polymerase Inhibitor, AG14361, Sensitizes Cells to Topoisomerase I Poisons by Increasing the Persistence of DNA Strand Breaks

N. Curtin, E. Willmore, Lisa M. Smith, 2005, Clinical Cancer Research.

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

N. Curtin, D. Newell, A. Calvert, 2001, British Journal of Cancer.

Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.

N. Curtin, I. Hardcastle, R. Griffin, 2005, Journal of medicinal chemistry.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

N. Curtin, I. Hardcastle, R. Griffin, 2007, Journal of medicinal chemistry.

8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).

N. Curtin, I. Hardcastle, R. Griffin, 2008, Bioorganic & medicinal chemistry letters.

Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.

A. Harris, N. Curtin, 1988, Biochemical pharmacology.

Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.

N. Curtin, P. Smith, D. Newell, 1999, Seminars in oncology.

Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors.

N. Curtin, I. Hardcastle, R. Griffin, 2010, Organic & biomolecular chemistry.

Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer

N. Curtin, C. Robson, A. Rigas, 2007, Oncogene.

Warburg and Krebs and related effects in cancer

N. Curtin, J. Unterlass, 2019, Expert Reviews in Molecular Medicine.

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.

N. Curtin, R. Griffin, B. Golding, 2004, Bioorganic & medicinal chemistry letters.

Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity

N. Curtin, R. Griffin, D. Newell, 2005, Journal of Pharmacology and Experimental Therapeutics.

Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines

N. Curtin, R. Griffin, B. Golding, 2002 .

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

N. Curtin, E. Willmore, P. Znojek, 2014, British Journal of Cancer.

R. Mangano, J. Sludden, Y. Drew, 2016, British Journal of Cancer.

Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.

A. Harris, N. Curtin, M. Bassendine, 1987, Journal of hepatology.

Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?

N. Curtin, J. L. Le Quesne, K. Bányai, 2020, British journal of pharmacology.

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

N. Curtin, B. Telfer, D. Hirst, 2009, Clinical Cancer Research.

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

J. Sarkaria, N. Curtin, P. Decker, 2009, Molecular Cancer Therapeutics.

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy

N. Curtin, M. Javle, Nicola J. Curtin, 2011, Therapeutic advances in medical oncology.

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Y. Drew, A. Boddy, N. Curtin, 2009, Clinical Cancer Research.

Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly ( ADP-ribose ) Polymerase

N. Curtin, R. Griffin, B. Golding, 2022 .

Pemetrexed disodium, a novel antifolate with multiple targets.

N. Curtin, A. Hughes, Nicola J. Curtin, 2001, The Lancet. Oncology.

Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors

N. Curtin, 2012 .

Poly(ADP-ribose) polymerase inhibition: past, present and future

N. Curtin, C. Szabó, 2020, Nature reviews. Drug discovery.

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

N. Curtin, R. Griffin, B. Golding, 2003, Journal of medicinal chemistry.

Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

N. Curtin, L. Pemberton, R. Griffin, 1998, Journal of medicinal chemistry.

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

N. Curtin, B. Durkacz, D. Newell, 2004, Clinical Cancer Research.

Preclinical Development The Clinically Active PARP Inhibitor AG 014699 Ameliorates Cardiotoxicity but Does Not Enhance the Ef fi cacy of Doxorubicin , despite Improving Tumor Perfusion and Radiation Response in Mice

N. Curtin, B. Telfer, K. Williams, 2011 .

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

N. Curtin, B. Telfer, K. Williams, 2011, Molecular Cancer Therapeutics.

Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro.

N. Curtin, D. P. Turner, Nicola J. Curtin, 1999, European journal of cancer.

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

N. Curtin, G. Shapiro, C. Robson, 2009, British Journal of Cancer.

The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

Y. Drew, N. Curtin, F. Zenke, 2022, Cells.

InhibitorRucaparib inOrthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

J. Sarkaria, J. Sludden, A. Boddy, 2015 .

The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.

N. Curtin, G. Mufti, F. Farzaneh, 2017, Methods in molecular biology.

The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients.

N. Curtin, G. Mufti, F. Farzaneh, 2011, Methods in molecular biology.

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells

N. Curtin, D. Harrison, H. Bryant, 2021, Cancers.

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

N. Curtin, R. Griffin, B. Golding, 2009, Molecular Cancer Therapeutics.

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

N. Curtin, W. Ciszewski, J. Dastych, 2013, Breast Cancer Research and Treatment.

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.

Y. Drew, D. Jamieson, N. Curtin, 2018, Blood advances.

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – A population pharmacokinetic/pharmacodynamic analysis of rucaparib

N. Curtin, R. Plummer, K. Kern, 2015, Clinical pharmacology in drug development.

Edinburgh Research Explorer Visualization of a DNA-PK/PARP1 complex

L. Pearl, N. Curtin, E. Morris, 2018 .

Visualization of a DNA-PK/PARP1 complex

L. Pearl, N. Curtin, E. Morris, 2012, Nucleic acids research.

PARP inhibitors target ATM+p53-defective gastric cancer

N. Curtin, 2014, Cell cycle.

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

N. Curtin, R. Maxwell, D. Newell, 2017, NMR in biomedicine.

Benzopyranone DNA-PK inhibitors

N. Curtin, P. Workman, I. Hardcastle, 2002 .

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

N. Curtin, D. Newell, D. Blakey, 2001, British Journal of Cancer.

Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines.

A. Boddy, N. Curtin, X. Lu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

N. Curtin, R. Griffin, B. Golding, 1995, Biochimie.

Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy

N. Curtin, I. Kotsopoulos, A. Mukhopadhyay, 2022, Cancers.

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

N. Curtin, D. Tweddle, Lindi Chen, 2020, Cancers.

Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer

N. Curtin, R. Plummer, C. Robson, 2011, PLoS ONE.

Chemical Therapeutics Preclinical Evaluation of a Novel ATM Inhibitor , KU 59403 , In Vitro and In Vivo in p 53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013 .

Effect of chronic N,N-diethylnitrosamine on the excision of O6-ethylguanine from rat liver DNA.

N. Curtin, A. Craig, K. Snell, 1979, British Journal of Cancer.

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

Y. Drew, N. Curtin, Hannah L. Smith, 2022, bioRxiv.

Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself

N. Curtin, B. Telfer, D. Hirst, 2015, PloS one.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

David Jamieson, Ruth Plummer, D. Jamieson, 2016, Journal of hepatology.

High‐resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers

D. Jamieson, A. Boddy, N. Curtin, 2015, International journal of cancer.

Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting

Y. Drew, N. Curtin, R. O'Donnell, 2020, Cancers.

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

N. Curtin, C. Szabó, 2013, Molecular aspects of medicine.

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Y. Drew, N. Curtin, S. Hall, 2019, Pharmacology & therapeutics.

PARP and PARP Inhibitor Therapeutics

N. Curtin, 2013 .

The role of PARP in DNA repair and its therapeutic exploitation

N. Curtin, N J Curtin, M. Javle, 2011, British Journal of Cancer.

Therapeutic potential of drugs to modulate DNA repair in cancer

N. Curtin, 2007, Expert opinion on therapeutic targets.

Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP).

N. Curtin, J. K. Porteous, L. Pemberton, 1995, Anti-cancer drug design.

Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

S. Snyder, R. Clark, N. Curtin, 2018, British journal of pharmacology.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

N. Curtin, R. Griffin, B. Golding, 2004, Journal of medicinal chemistry.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Robert Almassy, Kaye J Williams, N. Curtin, 2004, Journal of the National Cancer Institute.

Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.

M. Noble, J. Endicott, N. Curtin, 2006, Journal of the American Chemical Society.

The impact of p53 status on cellular sensitivity to antifolate drugs.

N. Curtin, J. Lunec, X. Lu, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

N. Curtin, S. Jackson, P. Reaper, 2004, Cancer Research.

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.

N. Curtin, R. Griffin, B. Golding, 2000, Journal of medicinal chemistry.

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

N. Curtin, R. Griffin, B. Golding, 1998, British Journal of Cancer.

Novel Benzimidazole and Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP‐ribose)polymerase*

N. Curtin, R. Griffin, B. Golding, 1996 .

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Per Källblad, N. Curtin, H. Willems, 2005, Bioorganic & medicinal chemistry letters.

Poly(ADP-ribose) polymerase inhibition: past, present and future

N. Curtin, C. Szabó, 2020, Nature Reviews Drug Discovery.

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

N. Curtin, P. Smith, Peter G. Smith, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody.

K. Sikora, N. Curtin, M. Bassendine, 1986, Journal of hepatology.

Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo.

N. Curtin, K. Snell, 1983, British Journal of Cancer.

Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

A. Harris, N. Curtin, M. Bassendine, 1986, British Journal of Cancer.

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

N. Curtin, R. Griffin, Yan Zhao, 2006, Cancer research.

Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.

N. Curtin, Peter G. Smith, R. Griffin, 2004, Journal of medicinal chemistry.

Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines).

N. Curtin, R. Griffin, B. Golding, 1994, Anti-cancer drug design.

Targeting the DNA damage response for cancer therapy

N. Curtin, 2023, Biochemical Society transactions.

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.

Yuzhu Chen, M. Noble, J. Endicott, 2004, Journal of medicinal chemistry.

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

L. Johnson, M. Noble, J. Endicott, 2002, Journal of medicinal chemistry.

Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.

A. Harris, N. Curtin, G. Aherne, 1991, Cancer research.

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.

M. Noble, J. Endicott, N. Curtin, 2007, Organic & biomolecular chemistry.

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.

N. Curtin, I. Hardcastle, R. Griffin, 2011, European journal of cancer.

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

Kwok-Kin Wong, N. Curtin, R. Bronson, 2011, Nature Medicine.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Y. Drew, N. Curtin, Z. Hostomský, 2011, Journal of the National Cancer Institute.

DNA damage checkpoint kinases in cancer

N. Curtin, D. Tweddle, Hannah L. Smith, 2020, Expert Reviews in Molecular Medicine.

Targeting DNA Damage Response Pathways in Cancer

N. Curtin, G. Abdulrahman, 2017 .

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity

N. Curtin, R. Edmondson, P. Cross, 2016, International Journal of Gynecologic Cancer.

Biomarkers for PARP Inhibitors

N. Curtin, Ricky A. Sharma, C. Dearman, 2015 .

Defective homologous recombination in human cancers.

N. Curtin, R. Edmondson, E. Plummer, 2012, Cancer treatment reviews.

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

N. Curtin, R. Griffin, Yan Zhao, 2011, Molecular Cancer Therapeutics.

DNA repair dysregulation from cancer driver to therapeutic target

Nicola J. Curtin, N. Curtin, 2012, Nature Reviews Cancer.

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2

N. Curtin, D. Newell, Y. Schlosser, 2017, Oncotarget.

Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

N. Curtin, 2013, British journal of pharmacology.

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

N. Curtin, B. Vormoor, 2014, Current opinion in oncology.

Inhibition of DNA Repair as a Therapeutic Target

N. Curtin, S. Veuger, 2014 .

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

N. Curtin, J. Lunec, R. Edmondson, 2017, Oncotarget.

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

N. Curtin, D. Tweddle, Lindi Chen, 2020, Frontiers in Oncology.

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.

P. Maxwell, N. Curtin, W. McCluggage, 2012, Cancer research.

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Y. Drew, N. Curtin, Z. Hostomský, 2010, Clinical Cancer Research.

Therapeutics , Targets , and Chemical Biology Cancer Research 6-Thioguanine Selectively Kills BRCA 2-Defective Tumors and Overcomes PARP Inhibitor Resistance

A. Harris, N. Curtin, Ricky A. Sharma, 2010 .

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

David C. Smith, N. Curtin, L. Byers, 2017, Cancer discovery.

Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)

M. Noble, N. Curtin, J. Tucker, 2017, Oncotarget.

Targeting the ATR-CHK1 Axis in Cancer Therapy

Y. Drew, N. Curtin, S. Rundle, 2017, Cancers.

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies

N. Curtin, G. Mufti, F. Farzaneh, 2013, Haematologica.

Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors

N. Curtin, J. Pollard, Jack Pollard, 2018 .

ATR as a Therapeutic Target

N. Curtin, Fiona K. Middleton, 2013 .

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

J. Sarkaria, N. Curtin, W. Cliby, 2011, British Journal of Cancer.

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.

M. Noble, N. Curtin, J. Tucker, 2016, Oncotarget.

PARP inhibitors for cancer therapy

N. Curtin, Nicola J Curtin, 2005, Expert Reviews in Molecular Medicine.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

N. Curtin, R. Plummer, P. Lorigan, 2013, Cancer Chemotherapy and Pharmacology.

Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.

N. Curtin, B. Durkacz, G. Smith, 2003, Cancer research.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

N. Curtin, D. Newell, Lan Z. Wang, 2007, Molecular Cancer Therapeutics.

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors

N. Curtin, J. Lunec, I. Kotsopoulos, 2016, International Journal of Gynecologic Cancer.

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

N. Curtin, M. Cole, J. Lunec, 2015, Oncotarget.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

A. Harris, N. Curtin, Ricky A. Sharma, 2010, Cancer research.

First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors

D. Matei, N. Curtin, J. Bono, 2013 .

Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.

Y. Drew, J. Ledermann, G. Hall, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

J. Sarkaria, J. Sludden, A. Boddy, 2015, Molecular Cancer Therapeutics.

EfficacyofPARP InhibitorRucaparib inOrthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

J. Sarkaria, J. Sludden, J. Murray, 2015 .

Targeting the DNA Damage Response for Anti-Cancer Therapy

N. Curtin, J. Pollard, Jack Pollard, 2018, Cancer Drug Discovery and Development.

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

A. Harris, A. Boddy, N. Curtin, 2008, Clinical Cancer Research.

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib

J. Murray, N. Curtin, P. Donoghue, 2016, Clinical Cancer Research.

Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.

N. Curtin, F. Campbell, D. Newell, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

N. Curtin, I. Hardcastle, R. Griffin, 2013, Journal of medicinal chemistry.

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

N. Curtin, Hannah L. Smith, L. Prendergast, 2020, Cancers.

DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival

N. Curtin, G. Shapiro, Clara Alsinet, 2014, Clinical Cancer Research.

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

N. Curtin, A. Lau, Yan Zhao, 2013, Molecular Cancer Therapeutics.

The Impact of p 53 Status on Cellular Sensitivity to Antifolate Drugs 1

N. Curtin, J. Lunec, D. Newell, 2001 .

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

N. Curtin, M. Cole, S. Coulthard, 2009, British Journal of Cancer.

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

A H Calvert, E. Sausville, L. Johnson, 2000, Journal of medicinal chemistry.

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples

N. Curtin, R. Sharrock, R. Edmondson, 2014, British Journal of Cancer.

PARP inhibitors for anticancer therapy.

N. Curtin, 2014, Biochemical Society transactions.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

N. Curtin, S. Kyle, H. Thomas, 2008, The British journal of radiology.

CHAPTER 12 – Inhibition of DNA repair as a therapeutic target

N. Curtin, T. Helleday, 2008 .

Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair

N. Curtin, B. Durkacz, Graeme C. Smith, 2004, Oncogene.

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

J. Bergh, C. Sotiriou, B. Gusterson, 2012, Breast.

Kinase and Poly ( ADP-Ribose ) Polymerase-1 ProteinCombined Use of Novel Inhibitors of DNA-dependent Radiosensitization and DNA Repair Inhibition by the Updated Version

N. Curtin, B. Durkacz, G. Smith, 2003 .

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

N. Curtin, J. Allan, M. Wade, 2015, Oncotarget.

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

N. Curtin, R. Plummer, R. Edmondson, 2011, BJOG : an international journal of obstetrics and gynaecology.

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

Y. Drew, N. Curtin, Sweta Sharma-Saha, 2019, Nature Reviews Clinical Oncology.

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity

N. Curtin, 2020, Cancers.

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Y. Drew, N. Curtin, E. Matheson, 2019, Cancers.

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.

Y. Drew, N. Curtin, E. Matheson, 2019, Biochemical pharmacology.

Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer

Y. Drew, N. Curtin, R. O'Donnell, 2020, Journal of Clinical Pathology.

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Adrian L Harris, A. Harris, A. Boddy, 2005, Clinical Cancer Research.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699

Y. Drew, A. Boddy, N. Curtin, 2010, British Journal of Cancer.

PARP inhibitor development for systemic cancer targeting.

N. Curtin, T. Zaremba, 2007, Anti-cancer agents in medicinal chemistry.

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation

N. Curtin, Fiona K. Middleton, J. Pollard, 2018, Cancers.

Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells.

N. Curtin, R. N. Turner, 1996, British Journal of Cancer.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

N. Curtin, R. Griffin, B. Golding, 2002, Journal of medicinal chemistry.

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

N. Curtin, D. Newell, D. Blakey, 2002, European journal of cancer.

In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity 1 , 2

N. Curtin, Peter G. Smith, R. Griffin, 2001 .

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport

N. Curtin, P. Smith, D. Newell, 2000, British Journal of Cancer.

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

N. Curtin, M. Cole, H. Thomas, 2010, Cancer Chemotherapy and Pharmacology.

Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations

N. Curtin, V. Speirs, T. Ward, 2021, The journal of pathology. Clinical research.

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor

Y. Drew, N. Curtin, J. Lunec, 2018, Cancer medicine.

DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

N. Curtin, I. Hardcastle, R. Griffin, 2010, Journal of medicinal chemistry.

The Enhanced Repair of O 6 -Alkylguanine in Mammalian Systems

J. Ashby, J. Styles, N. Curtin, 1981 .

Dipyridamole Damage , and Growth Inhibition following Exposure to CB 3717-triphosphate Accumulation , DNA ′-Deoxyuridine-5 ′ Inhibition : 2 Mechanism of Cell Death following Thymidylate Synthase Updated

A. Harris, G. Wynne, N. Curtin, 2006 .

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

N. Curtin, M. Cole, S. Coulthard, 2011, The Biochemical journal.

Strategies employed for the development of PARP inhibitors.

N. Curtin, K. Maegley, Stacie Canan, 2011, Methods in molecular biology.

mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

N. Curtin, R. Plummer, P. Stephens, 2016, Molecular oncology.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

N. Curtin, B. Durkacz, D. Newell, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.

N. Curtin, S. Barton, R. Griffin, 2001 .

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

J. Murray, A. Boddy, N. Curtin, 2014, British Journal of Cancer.

Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide

A. Harris, A. Boddy, N. Curtin, 2005 .

Hypoxanthine transport in human tumour cell lines: relationship to the inhibition of hypoxanthine rescue by dipyridamole.

N. Curtin, D. Newell, E. Marshman, 2001, Biochemical pharmacology.

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding

N. Curtin, R. Griffin, B. Golding, 1999, British Journal of Cancer.

349 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)

N. Curtin, R. Plummer, B. Vormoor, 2012 .

Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.

A. Harris, N. Curtin, D. Newell, 1989, Biochemical pharmacology.

Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer

Y. Drew, N. Curtin, R. O'Donnell, 2021, Cancers.

Overcoming PARP inhibitor resistance by inducing a homologous recombination repair defective phenotype with ATR, CHK1 and WEE1 inhibitors

N. Curtin, Hannah L. Smith, E. Willmore, 2023, bioRxiv.

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer

N. Curtin, P. Bai, 2020, Cancers.

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

N. Curtin, R. Edmondson, P. Cross, 2016, International Journal of Gynecological Cancer.

Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage.

N. Curtin, G. Aherne, R. N. Turner, 1997, British Journal of Cancer.

Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer

M. Noble, N. Curtin, J. Tucker, 2016, Oncotarget.

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

N. Curtin, D. Newell, D. Blakey, 2000, British Journal of Cancer.

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

N. Curtin, J. Lunec, R. Edmondson, 2017, OncoTarget.